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Bovine respiratory disease (BRD) is a multifactorial disease complex that is common in feedlot 
operations, where it causes major economic loss through: reduction in average daily gain, 
treatment costs, and mortality.  Reducing BRD incidence would increase profits to producers, 
reduce antimicrobial use, and improve animal welfare.  Two studies were performed to compare 
clinical vaccine response.  First, a randomized control study enrolled 75 crossbred heifer calves 
into an injectable modified live viral (IJ-MLV) group, intranasal homologous boost (IN-MLV) 
group, or intranasal heterologous boost (IN-KV) group.  Vaccines were administered at birth, 
‘‘turnout’’ (~2 months of age), and weaning.  Blood samples and weights were collected at 
‘turnout’, two weeks post ‘turnout’, weaning, and two weeks post weaning, with weights also 
being collected at birth and 87 days post weaning.  Blood samples were analyzed with an ELISA 
for bovine respiratory syncytial virus (BRSV) and bovine herpes virus type 1 and virus 
neutralization for bovine viral diarrhea virus types 1 and 2.  No differences were observed 
between the average daily gains of the three groups.  The IN-KV group had significantly higher 
BRSV antibody concentrations than the other groups at all time points except for ‘turnout’ but 
had lower bovine viral diarrhea virus type 2 concentrations at weaning and two weeks post 
weaning.   
Next, a field study was conducted at two commercial ranches in central Saskatchewan, enrolling 
645 calves from one farm and 481 calves from a second farm.  The calves were randomly 
enrolled by vaccine type at branding into either an IJ-MLV group or IN-MLV group.  Calves 
were managed extensively, until weaning when they were moved to a local feedlot.  At the 
feedlot calves were vaccinated and separated into steer and heifer pens and were monitored daily 
for disease.  Weights were collected upon arrival and at 60 days post weaning.  Morbidity and 
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mortality due to bovine respiratory disease and average daily gains were analyzed.  The results 
show no significant difference between the two groups for these outcomes.  These two studies 
show the importance of considering vaccine type and administration route when developing 
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Bovine respiratory disease (BRD) is an important disease complex to the beef cattle industry, 
impacting cow-calf operations, stockers, and feedlots.  Newly weaned calves are highly 
susceptible to respiratory disease because of the stress of weaning and the mixing that occurs in 
auction markets and feedlots.  In feedlot cattle, morbidity rates averaged 16% in 2011 
(Aphis.usda.gov, 2013, a), and mortalities ranged from 1.00 – 1.75% (Miles et al., 2009).   
Metaphylactic antibiotics are commonly used in feedlots at calf arrival to help reduce disease in 
weaned calves that are at high risk of BRD. Increasing public awareness related to antimicrobial 
use in livestock agriculture has led to Canadian national activities to understand current 
antimicrobial use in the Canadian Beef Industry, with the goals of promoting antimicrobial 
stewardship and best practices, while still supporting animal welfare. (Cusack, 2004) (Prescott et 
al., 2012) (Cameron and McAllister, 2016).  Therefore, it is important for feedlot operations to 
adapt and create new methods of management to help reduce disease pressure on cattle or 
improve the immune system of the cattle to minimize antimicrobial usage.  This chapter will 
focus on understanding the importance of BRD to the Canadian beef industry and the viruses 
associated with it, outlining the key aspects of the bovine immune system, and describing 
vaccination as a control for BRD.  
1.2 Respiratory Disease in Pre and Post Weaned Calves 
Bovine respiratory disease is a multifactorial disease that affects cattle of all ages but is most 
prevalent in calves post weaning.  Various respiratory pathogens, both viral and bacterial, are 
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associated with the development of BRD (Murray et al., 2017) (Jones and Chowdhury, 2010).  
However, high BRD prevalence in recently weaned calves is also associated with risk factors 
including weaning stress, comingling of source groups, crowding in pens, transport conditions, 
and weather.  While risk factors do not directly cause respiratory disease, they contribute to 
immune system suppression, or increase contact between animals, therefore, the chance of 
exposure to disease (Belasco et al., 2015) (Taylor et al., 2010).  Bovine respiratory disease is 
important to the beef industry because it causes production losses through morbidity, mortality 
and reductions in average daily gain (ADG) (Brooks et al., 2011).  This section will discuss the 
economics associated with BRD, the important pathogens and risk factors associated with BRD. 
1.2.1 Economic Loss Due to BRD  
Bovine respiratory disease is a disease complex with the largest economic impact on the cattle 
feeding industry.  In the United States, it was found that BRD morbidity averaged 16% across 
various feedlots (Aphis.usda.gov, 2013, a).  Economic losses related to BRD occur through 
treatment costs, which have been seen as high as $23.60USD/calf, and decreased carcass weight 
averaging $100/calf (Aphis.usda.gov, 2013, a) (Smith, 2009).  Mortality is also an important 
cause of economic loss.  Mortality rates for calves range depending on cattle population type and 
can vary from 1.0%, among older heavier classes of cattle to 1.75% in younger lighter classes of 
cattle (Miles et al., 2009).  Overall BRD increases the cost of calf production and reduces the 
value of the calves upon sale (Cernicchiaro et al., 2013). 
1.2.2 Pathogens Associated with BRD 
Multiple viral and bacterial pathogens are associated with BRD.  Viral pathogens associated with 
BRD include bovine respiratory syncytial virus (BRSV), bovine herpes virus type 1 (BoHV1), 
and parainfluenza 3 virus (Miles, 2009).  Bovine viral diarrhea virus (BVDV) is a major virus 
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associated with BRD, but does not cause respiratory disease (Ridpath, 2010).  Viruses are 
usually the initial infector causing a weakened immune system in the animal making infection by 
bacteria more likely (Panciera and Confer, 2010).  The major bacterial pathogens associated with 
BRD are Manheimia haemolytica, Mycoplasma bovis, Histophilus somni, and Pasturella 
multocida (Booker et al., 2008).   
1.2.3 Bovine Respiratory Syncytial Virus (BRSV) 
Bovine respiratory syncytial virus is one of the most important viruses associated with BRD.  
This virus suppresses the immune system increasing the opportunity for secondary bacterial 
infections to occur (Brodersen. 2010).  The immune system of the calf is triggered by the 
presence of G and F proteins, major surface proteins of BRSV, detected by Toll-like receptor-4 
(Gershwin. 2007) (Gershwin. 2012).  This recognition results in the production of inflammatory 
cytokines, while dendritic cells work to initiate an immune response by T-cells.  However, 
BRSV has been shown to infect dendritic cells, disrupting their function, and thereby weakening 
the immune response (Gershwin. 2012).  The weakened immune response results from decreased 
interferon gamma (IFN-y) release by dendritic cells, which allows the BRSV virus to evade 
clearance by cytotoxic immune cells (Bueno et al., 2008).  The evasion of clearance by the 
immune system allows BRSV to multiply and spread.   
Bovine respiratory syncytial virus causes clinical signs such as fever, coughing, and nasal 
discharge which begin approximately four days after infection, and last for about ten days if no 
secondary infection occurs (Woolums, 1999).  Bovine respiratory syncytial virus is spread 
between calves through nasal secretions and aerosolized droplets (Woolums, 1999).   
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1.2.4 Bovine Herpes Virus type 1 (BoHV1) 
Bovine herpes virus type 1 is a major virus implicated in the development of BRD, and a primary 
pathogen that suppresses the immune system.  Immune suppression occurs by disrupting the 
function of major histocompatibility complex 1 transporters, causing a decrease in cluster of 
differentiation 8+ T cell response.  The cluster differentiation 4+ T cells also become infected by 
BoHV1, resulting in cell lysis (Jones and Chowdhury, 2010).  In response to BoHV1 infection, 
the immune system increases the production of cortisol, interferon-y, and white blood cells 
(Falkenburg et al., 2013) (Babiuk et al., 1996) (Myulkens et al., 2007). 
The most common clinical signs involved with BoHV1 infection include fever, coughing, 
anorexia, nasal discharge, and dyspnea in the larynx, these appear approximately four to five 
days post infection (Myulkens et al. 2007).  Recovery from BoHV1 begins approximately five 
days after onset of clinical signs.  The illness can become worse due to spread of BoHV1, or 
secondary bacterial infection (Nataraj et al., 1997).  Bovine herpes virus type 1 is spread through 
nasal secretions and aerosolized droplets (Jones and Chowdhury, 2010). 
1.2.5 Bovine Viral Diarrhea Virus Types 1 and 2 (BVDV1, BVDV2) 
Bovine viral diarrhea virus types 1 and 2 are important factors in the development of BRD, but 
these viruses are not always viewed as a direct cause respiratory disease.  However, BVDV 1 and 
2 cause immunosuppression, resulting in calves to be at higher risk for developing BRD.  
Mechanisms of immunosuppression from BVDV have been established, linked to both innate 
and acquired immunity.  These include downregulation of major histocompatibility complex II 
and interleukin 2, causing suppression of T-helper cell responses, and decreasing the production 
of interferons (Van Wyk, 2016) (Ridpath, 2010). 
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Feedlot calves are commonly exposed to BVD 1 and 2 through exposure to persistently infected 
(PI) calves.  Calves become PI when the dam is infected with BVDV between 45 and 120 days 
with BVDV, and the virus spreads to the fetus.  At this time, the fetus’ immune system is just 
starting to develop and will recognize not recognize BVDV as a pathogen; therefore, it will not 
create antibodies against it (Van Wyk, 2016).  Persistently infected calves act as vectors and 
spread the virus without showing clinical signs.  Bovine viral diarrhea virus is spread by oral or 
mucosal contact with secretions from other calves containing BVDV (Falkenburg et al., 2018) 
(Ridpath, 2010).  Studies have shown the presence of PI calves in feedlot pens cause an increase 
in BRD morbidity in their home pen and adjacent pens (Richeson et al., 2012).  It has also been 
found that pens with PI calves had a lower average daily gain from days 14-28, and a higher 
incidence rate of BRD (Groom et al., 2014). 
1.2.6 Parainfluenza 3 Virus (PI3) 
Parainfluenza 3 is a direct causative agent of respiratory disease, as it is restricted specifically to 
the airway (Eberle et al. 2015) (Ogunbiyi et al. 1988).  Often the calves that are most at risk 
include naïve calves that have not received enough colostrum, or received poor quality colostrum 
(Marshall and Frank, 1975).  Clinical signs associated with PI3 infections are mild; however, the 
virus causes immunosuppression that may lead to a secondary bacterial infection.  Infected 
calves become immunosuppressed through the inhibition of interferon I and interferon III by PI3 
resulting in decreased signaling ability of the immune system (Eberle et al., 2015).  Viral 
infection by PI3 also decreases the strength of the innate immune systems response by 
replicating in macrophages and decreasing their ability to affect foreign invaders (Ellis, 2010, a).  
Clinical signs associated with PI3 include pyrexia, coughing, nasal discharge, and shallow 
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breaths (Ellis. 2010, a).  Parainfluenza 3 is transmitted through aerosolized particles containing 
virus (Ellis, 2010, a).   
1.2.7 Mannheimia Haemolytica 
Mannheimia haemolytica is a bacterial pathogen known to cause a severe bronchopneumonia in 
calves.  However, M. haemolytica is part of the normal flora of the upper respiratory tract.  The 
commensal strain of M. haemolytica is A2 and is predominantly found in healthy calves.  When 
the calf’s immune system is compromised by stress or a primary viral pathogen, the infectious 
A1 strain becomes dominant (Griffin et al., 2010).  Mannheimia haemolytica evades detection by 
the immune system through formation of a biofilm with extracellular polymeric substance 
(Boukahil and Czuprynski, 2016).  The main virulence factor of M. haemolytica is leukotoxin.  
Leukotoxins interact with the B2+ integrins of leukocytes, causing apoptosis by upregulating 
calcium intake, inhibiting the functionality of phagocytosis, inflammation, antigen presentation, 
and cytotoxicity (Griffin et al., 2010).  Mannheimia haemolytica has a lipopolysaccharide 
complex, which acts as an endotoxin that causes recruitment of cytokines into the lung tissue, as 
well as apoptosis and necrosis (Craddick et al., 2012).  Infection due to M. haemolytica can cause 
coagulative necrosis of the lung tissue leading to bronchopneumonia (Griffin et al., 2010).   
1.2.8 Other Associated Pathogens  
Pasturella multocida is a bacterial pathogen that causes secondary infection in 
immunosuppressed calves.  Pasturella multocida is a commensal bacterium of the upper 
respiratory tract, but when the calf’s immune system is compromised, it can migrate to the lower 
respiratory tract and act as a pathogen (Griffin et al., 2010).  Cranioventral bronchopneumonia is 
typically associated with P. multocida.  This bacterial pathogen is excreted in nasal secretions 
and colonizes the respiratory tract after inhalation of the bacteria (Dabo et al., 2007). 
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Histophilus somni is another commensal bacterium that regularly colonizes the nasopharyngeal 
region of the upper respiratory tract.  This bacterium is mainly involved in secondary infection 
with BRD.  Histophilus somni has been associated with several disease manifestations such as 
fibrinopurulent bronchopneumonia, abscessing laryngitis, septicemic-related cardiovascular 
necrosis, fibrinous pericarditis and meningoencephalitis (Griffin et al., 2010).  This bacterial 
pathogen is spread through nasal secretions and colonizes the respiratory tract after inhalation of 
the bacteria. 
Mycoplasma bovis is isolated from the upper respiratory tract of healthy calves and is also found 
on mucosal surfaces of the urinary tract, genital tract, and in milk.  This bacterial species has 
been found to act mainly as a secondary infection, but some evidence suggests it can be a 
primary pathogen as well (Schibrowski et al., 2014).  When the host is immunosuppressed M. 
bovis has the opportunity to become pathogenic, often causing chronic disease.  A major 
symptom of M bovis infection is a caseonecrotic bronchopneumonia, with nodules of caseous 
necrosis within them (Schibrowski et al., 2014).  This pathogen is spread mainly through animal 
to animal contact but can also be obtained through the environment (Griffin et al., 2010). 
1.2.9 Stress as a Factor in BRD development  
Psychological and physical stress, such as weaning, comingling with new calves, and animal 
handling can suppress the immune system of calves.  These stresses promote glucocorticoid 
production by the adrenal gland.  Glucocorticoids affect the innate immune system by 
suppressing white blood cell recruitment and decreasing white blood cells ability to infiltrate the 
infected area (Schleimer, 2004).  Glucocorticoids also act to suppress the acquired immune 
system by decreasing T-helper cell proliferation, resulting in reduced amounts of cytotoxic T-
cells, and decreased B-cell maturation (Pruett, 2003) (Schleimer, 2004) (Priyadarshini and Aich, 
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2012).  Prolonged stress causes a constant influx of glucocorticoids, resulting in prolonged 
suppression of the immune system (Carroll and Forsberg, 2007). 
One of the most important causes of stress in calves is weaning. Weaning is the time period 
when the calf is separated from its dam, and in the Canadian Beef Industry this is usually 
followed by transport to a feedlot or backgrounding lot.  Transport is also a major stress due to 
close animal contact within trucks, the potential for extended transport time, and the possibility 
of exposure to temperature extremes in transit (Bach, 2004) (Sconberg et al., 1993).  After 
arriving at the feedlot, the calves may encounter many more stresses such as: feed changes, 
extreme weather fluctuations, and adverse pen conditions at times (Arthington et al., 2008) 
(Smith et al. 2001) (Belasco et al., 2015).  This stressful period will increase the level of 
glucocorticoids released by the calf (possibly over a prolonged period of time), which may result 
in a weakened immune system.  As part of arrival processing procedures, the calf may then be 
vaccinated (Arthington et al., 2008).  Due to the stresses of weaning and transport, the calf’s 
immune system may not be able to respond appropriately to the vaccine(s), resulting in sickness. 
1.3 Bovine Immune System 
1.3.1 Innate Immune System 
The innate immune system is a first response defense against pathogens.  It is comprised of 
different types of defenses that respond to disease challenge rapidly.  The innate immune system 
is comprised of physical barriers, immune cells and chemicals in the blood (Galley and Webster, 
1996) (Murphy, 2012).  An example of a physical barrier which aids in the defense from disease 
is the skin.  Skin is non-permeable, and regularly sheds epithelium while simultaneously 
removing bacteria through a process called desquamation.  The epidermal surface of the skin is 
inhospitable to pathogen growth as it lacks the moisture required for colony establishment 
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(Eyerich et al., 2018). The upper respiratory tract and gastrointestinal systems act as another 
physical barrier to pathogen invasion and colonization (Murphy, 2012).  These systems have a 
mucociliary lining which captures pathogens and physically removes them.  The natural flora of 
these systems also acts to prevent colonization of foreign bacteria through competitive growth or 
secretion of toxic substances that inhibit the growth of pathogens (Cha et al., 2010) (Eyerich et 
al., 2018).  
The innate immune system also functions through the activation of the cellular immune response. 
For example, the complement system is a group of small proteins that aid the cellular immune 
system by binding to pathogens and marking them for attachment by the immune cells 
(Ghebrehiwet, 2016).  Complement activates the recruitment of inflammatory cells, but also 
increases the permeability of a pathogen’s membrane, resulting in lysis and cell death (Gurao et 
al., 2017). 
The activation of the inflammatory cascade is an important component of the innate immune 
system as this results in not only a nonspecific cellular response, but also a chemical response 
(Galley and Webster, 1996) (Tizard, 2013).  An example of the inflammatory cascade’s function 
is release of chemicals such as histamine, bradykinin, prostaglandins, etc. which cause 
vasodilation and subsequently increase blood flow to the area of infection.  This increase in local 
blood supply aids the recruitment of immune cells such as neutrophils (Luster et al., 2005).  The 
inflammatory system is an extensive system which includes many chemical cascades and cellular 
responses that are a part of the innate immune response.  The inflammatory system works 
synergistically with the nonspecific cellular response of innate immunity.  Leukocytes are an 
important part of the cellular response, and include natural killer cells, eosinophils, basophils and 
neutrophils.  Leukocytes function freely of other parts of the immune system, and circulate 
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extensively through the body removing cellular debris, foreign particles and invading 
microorganisms (Bromfield et al., 2011).  The innate immune response is an important first 
barrier to foreign invasion and functions via physical barriers, immune cells, and chemicals in 
the blood stream to remove or target foreign cells (Tizard, 2013) (Murphy, 2012).  
1.3.2 Acquired Immune System 
The acquired immune system is the part of the immune system that reacts to specific pathogens 
that have invaded the body.  It clears these pathogens through lysing of the pathogen, 
neutralization of toxins produced by the pathogen, or lysing the infected host cell (Tizard, 2013).  
Pathogens and toxins can present specific antigens on their exterior surface that can be 
recognized by the immune system.  Antigen recognition stimulates recruitment of B lymphocytes 
to an area (Nguyen et al., 2017), where the B lymphocytes mature and multiply into plasma cells.  
Plasma cells secrete antibodies specific to the recognized antigen.  The antibodies work to 
neutralize the pathogen or toxin through attachment, complement promotion, anti-toxin 
production, and macrophage recruitment (Ansel et al., 2002) (Murphy, 2012). 
The immune system also responds to antigens through recruitment of T lymphocytes.  T 
lymphocytes bind directly to the antigen on pathogens and then multiply and specialize into 
either cytotoxic T cells or T helper cells.  Cytotoxic T cells produce cytotoxins that cause lysis of 
the pathogen or infected cell.  Cytotoxic T cells also act by binding directly to the pathogen 
(Bedel et al., 2013), releasing first apoptosis signal (FAS) ligands, which lead to apoptosis of 
both cells.  T lymphocytes can also specialize into T helper cells.  T helper cells activate 
cytotoxic T cells, stimulate macrophage recruitment, and stimulate antibody production by B 
lymphocytes (Tizard, 2013) (Murphy, 2012) (Shedlock, Shen, 2003). 
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1.3.3 Vaccines and how they affect the immune system 
The innate immune system is the first line of defense against pathogens.  If this should fail, the 
acquired immune system is the second defense system.  However, the acquired immune system 
requires time to mount a response, leaving the animal vulnerable for a period of time (Galley and 
Webster, 1996).  If the acquired immune system has encountered an antigen previously, it is able 
to respond rapidly the next time it is exposed to the same antigen (Ramshaw and Ramsey, 2000) 
(Lu, 2009) (Kardani et al., 2016).  This natural mechanism of priming the immune system for 
response is the basis for vaccination. Vaccination is the priming of the immune system through 
exposure to specific pathogen antigens, allowing a more rapid response if natural exposure to the 
pathogen occurs at a later time point. 
Two of the most common types of vaccines used are modified live viral (MLV) vaccines and 
inactivated vaccines, which are often referred to as killed viral (KV) vaccines.  Modified live 
viral vaccines are produced by growing genetically modified viruses (Arevalo et al., 2015), or 
growing the pathogen under conditions which reduce the pathogenicity of the pathogen.  A major 
advantage of modified live vaccines is that the virus multiplies in the host, thus requiring a lower 
initial dose of virus in the vaccine.  Killed viral vaccines are produced by growing a pathogen, 
then neutralizing it through protein cross linking treatments, protein denaturation treatments, or 
heat treatments (Delrue et al., 2012).  These methods of pathogen production decrease the 
virulence of the pathogen, so it does not cause disease or multiply with in the host.  These 
methods of producing MLV and KV vaccines maintains the viruses’ exterior antigens, allowing 
the B lymphocytes to produce antibodies specific to the pathogen upon vaccination (Ansel et al., 
2002) (Murphy, 2012). 
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1.3.4 Maternal Antibody Interference 
An important challenge to vaccinating neonatal calves is interference by maternal antibodies 
(MatAb).  Maternal antibodies are obtained right after birth through the consumption of 
colostrum (Kehoe et al., 2011).  Colostrum is the first milk produced by the dam, and consists of 
vitamins, minerals, fat, leukocytes and antibodies from the dam’s immune system (Lago et al., 
2018).  During the first 6-12 hours of birth the gastrointestinal tract of the calf is permeable to 
large proteins, which allows the absorption of full antibodies from the colostrum.  These 
maternal antibodies are absorbed into the blood stream and provide the calf with immune 
protection (Heinrichs and Elizondo-Salazar, 2009).  Absorption of antibodies from colostrum 
provides the calf with immunity for the first three to four months of life.  Maternal antibodies are 
highly concentrated in colostrum and the antibody half-life is about four months of age (Munoz-
Zanzi et al., 2002).  Previous research has shown that injectable vaccination prior to four to five 
weeks of age does not result in a systemic immune response (Platt et al., 2009).  High 
concentrations of maternal antibodies interfere with vaccine effectiveness.  The mechanism for 
this interference isn’t definitively known, however, some theories exist.  One theory, called 
epitope masking, suggests that maternal antibodies bind to the vaccine antigen, preventing it 
from binding to B lymphocytes (Niewiesk, 2014).  The second theory suggests that the maternal 
antibodies bind to the B cell receptors and to the fragment crystallizable (Fc) receptors.  The 
attachment of maternal antibodies to Fc receptors inhibits the B lymphocytes’ ability to bind with 
vaccine antigens.  Both theories result in the inability of B lymphocytes to attach to vaccine 




Intranasal (IN) vaccines have shown potential to bypass MatAb interference and provide a 
priming response (Mahan et al., 2016) through the stimulation of alternate parts of the acquired 
immune system.  Intranasal vaccines prime the mucosal immune system, increasing 
immunoglobulin A (IgA), whereas maternal antibodies and injectable vaccines primarily affect 
the systemic immune system, increasing immunoglobulin G (IgG) (Griebel, 2009) (Walz et al., 
2017, 1).  In calves vaccinated intranasally, an IgA response was detected (based on nasal swab), 
whereas an IgG response in the blood was not detected (Hill et al., 2012).  This suggests a 
response in the calf’s mucosal immune system, but not its systemic immune system.  
Priming and boosting is a method used to increase the immune response to vaccination 
(Ramshaw and Ramsey, 2000) (Lu, 2009) (Kardani et al., 2016).  Priming is the first dose of the 
vaccine, which provides the antigens for the immune system to stimulate the production of 
antibodies and induce immune memory through B lymphocytes.  Boosting is a second dose of 
vaccine that provides antigens that the immune system recognizes.  This recognition of the 
antigen results in a quicker and more powerful immune response, known as an anamnestic 
response (Ramirez et al., 2009). 
In a previous study, calves were given an initial priming IN vaccine and then a second boosting 
IN vaccine; after the booster vaccine, IgA concentrations increased even further than those seen 
after the priming vaccine, indicating an even more effective immune response with the second 
dose (Hill et al., 2012).  This suggests that IN vaccination, in the face of maternal antibodies, 
may be an effective method to increase a calf’s immune protection and offer an increased 
antibody response upon revaccination.  
The prime-boost method of vaccination results in greater immune protection against disease.  
The most common method of prime-boost vaccination is through homologous vaccination 
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(Waldner et al., 2018).  Homologous vaccination refers to priming and boosting with the same 
type of vaccine.  Heterologous vaccination, rarely used in veterinary medicine, is based on 
priming and boosting with vaccines that are different, such as priming with a MLV vaccine and 
boosting with a KV vaccine (Kamble and Lee, 2016).  Heterologous vaccination has been 
researched primarily in human medicine (Lu S. 2009) to offer an increased immune response.  
An example is heterologous prime-boost vaccination against human immunodeficiency virus 
(HIV), in which the priming is through a deoxyribonucleic acid (DNA) vaccine, followed by an 
attenuated viral vector, which usually comes from a modified form of fowl pox virus or 
adenovirus strains (Ramshaw and Ramsay. 2000).  One reason that heterologous prime-boosting 
is more effective is the ability to stimulate different parts of the immune system.  An example is 
a subunit vaccine stimulating the humoral system, while a DNA or MLV vectors stimulate the 
cell mediated immune response (Kardani et al. 2016).  The cattle industry has yet to develop 
different vector vaccines, but the heterologous effect is thought to occur between modified live 
and killed viral vaccines to produce an increased anamnestic response (Bowland and Shewen, 
2000). 
1.4 Vaccination in Calves 
In the perinatal period, the only immunoglobulins present in calves’ immune systems are those 
derived from consumption of colostrum (Lago et al., 2018).  The immune system develops and 
begins creating antibodies as the calf ages and is exposed to antigens.  Vaccination is an 
important method to reduce the effect of natural exposure to disease as vaccines do not cause 
disease but still stimulate an immune response (Niewiesk, 2014).  Most vaccinations are 
administered through injection with a MLV vaccine at branding (Waldner et al., 2018).  Some 
producers use IN vaccines at branding, with a smaller number using KV vaccines (Waldner et 
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al., 2018).  However, there is still much research to be done to determine the best method of 
vaccination.  
1.4.1 Modified Live Viral (MLV) vaccine  
Modified live viral vaccines are produced through an attenuation process.  Attenuation is the 
process of reducing infectivity of pathogens.  There are various ways to accomplish attenuation.  
One method is through changing the growing condition of the target pathogen.  This different 
growing environment disables the virus’s ability to cause infection in the host, while maintaining 
its antigens (Arevalo et al., 2015).  This allows the immune system to create antibodies without 
risk of induction of disease.  Genetic modification is also used to develop MLV vaccine; the 
method of attenuation modifies the virus to be unable to replicate in the host, but retains its 
antigens (Tizard, 2013).   
1.4.2 Inactivated/Killed Viral (KV) vaccine  
The production of killed vaccines consist of using killed organisms or inactivated toxoids.  The 
primary method for inactivation or killing is the use of protein cross linking treatments, and 
protein denaturation treatments (Delrue et al., 2012).  This effectively kills the pathogen, 
removing its pathogenicity, while allowing its antigens to be recognized by the immune system, 
and antibodies to be created (Tizard. 2013).   
1.4.3 Vaccination Route 
The most common method of administering vaccines in the beef industry is through injection 
(Waldner et al., 2018), which includes intramuscular and subcutaneous routes of administration.  
Subcutaneous vaccination deposits a dose of the viral antigen into the animal’s fat layer, where 
antigen then gets absorbed into the bloodstream (Newcomer and Givens, 2016) (Niewiesk, 
2014).  In the bloodstream, B lymphocytes will bind to the antigens and specialize, creating 
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antibodies (Nguyen et al., 2017).  Intranasal administration is another route that is used, but it is 
less common than injectable methods (Waldner et al., 2018).  Intranasal vaccines stimulate the 
mucosal immune system, increasing production of antibodies to the affected area (Griebel, 
2009).  Oral vaccines are often used in human and companion animal medicine; however, they 
are not common in food animals.  (Woolums et al., 2013) (Kavanagh et al., 2013).  
1.5 MLV and Killed Vaccine Trials 
Studies have shown that MLV and KV vaccines can offer similar protection between animals.  
One study compared the blood titer levels of cows after revaccination for BVDV and BoHV1 in 
dairy cows with a KV or MLV, finding no difference (Walz et al., 2015) (Walz et al., 2017, b.  
Some vaccines can cause negative reactions in the host, as has been seen with BoHV1 vaccines 
which have caused abortion in pregnant cows (Walz et al., 2017).  It was initially thought that 
MLV vaccines caused more abortions due to remaining virulence of the vaccine virus.  However, 
studies have shown that there is no difference between the MLV and KV vaccines in regard to 
disease protection and calving rates (Dubovi et al., 2000).  Ellis et al. (2005) observed KV 
vaccinated calves had increased immune protection from BRSV when challenged compared to 
unvaccinated control calves, giving similar results as previous MLV vaccine trials (Ellis et al., 
2018).  This gives evidence that KV and MLV vaccines could offer similar protection against 
respiratory viruses. 
1.6 Intranasal vs. Injectable Vaccines 
Intranasal vaccines are used to prime the mucosal immune system and stimulate a localized 
immune response (Griebel, 2009) (Hill et al., 2012).  Intranasal vaccines have been shown to 
have a protective against BRD pathogens, primarily through increased IgA antibody 
concentrations for short durations, with minimal effect of IgG antibody concentrations 
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(Kavanagh et al., 2013).  Intranasal vaccines offer protection when administered as the primer 
and booster, and results in protection similar to that of injectable vaccines (Vangeel et al., 2007) 
(Vangeel et al., 2009).   
An issue that producers face with injectable vaccines is interference due to maternal antibodies 
(MatAb) (Niewiesk, 2014).  These MatAbs inhibit the immune system’s ability to respond to 
antigens, leaving them susceptible to disease after the MatAb concentrations have waned 
(Vangeel et al., 2007) (Nguyen et al., 2017).  Studies have shown that IN vaccines can cause 
improved protection to the calf, even in the face of MatAb, by bypassing MatAbs (Vangeel et al., 
2007) (Ellis et al., 2013).  This allows IN vaccines to be used as a primer, even in the face of 
MatAbs, and elicit an anamnestic response when boosted (Stokka et al., 2016) (Woolums et al., 
2013).  To properly test for effectiveness of IN vaccines in the face of maternal antibodies, 
mucosal IgA concentrations should be sampled, though some studies only test for IgG (Xue et 
al., 2010).  This is because IN vaccines elicit a high mucosal IgA response, while responding 
with no increase, or a small increase in systemic IgG (Kavanagh et al., 2013) (Hill et al., 2012). 
Often to determine the effectiveness of a vaccine or immune stimulating activity, researchers will 
use serology to determine antibody concentrations.  With IN vaccines, serology can be a 
misleading method of determining effectiveness, as IN vaccines do not always show increased 
systemic antibody concentrations, but rather show increased mucosal IgA antibody 
concentrations (Kavanagh et al., 2013) (Hill et al., 2012).  A study administered BRD vaccines to 
two groups of calves, one intranasally and one through injection.  A polymerase chain reaction 
(PCR) was done to determine if the antigen from vaccines could be differentiated from natural 
viral antigens.  The results show that both IN and injectable (IJ) vaccines could be detected 
through PCR performed on nasopharyngeal swabs or deep tracheal washes (Walz et al., 2017, a).  
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This gives evidence that IJ vaccines can impact the mucosal immune system.  There is also 
evidence that IN vaccines can increase IgG antibodies in the system immune system (Grissett et 
al., 2014). 
Another method to determine effectiveness of IN vaccines in the face of MatAbs is through 
morbidity and mortality, which is commonly used (Ellis et al., 2010, a) (Vangeel et al., 2007, a) 
(Ellis et al., 2013) (Vangeel et al., 2007, b).  Morbidity and mortality studies have shown that IN 
vaccines had a disease sparing effect in IN vaccinated calves compared to control calves 
(Vangeel et al., 2007, a) (Xue et al., 2010).  Intranasal vaccines have been observed to reduce the 
rate of MatAb waning, resulting in a longer lasting protection to the calf (Xue et al., 2010).  
While antibody concentrations are useful to determine significant differences, they may not be 
clinically relevant.  To determine if vaccination methods have a clinical difference, morbidity 
data is often used.  Multiple challenge studies have shown that IN vaccines are able to reduce the 
morbidity due to BRD (Vangeel et al., 2007, b) (Xue et al., 2010) (Ellis et al., 2007) (Ellis et al., 
2010, b).  This contrasts with results from studies that used only IgG concentrations as the 
determinant for vaccine efficacy (Kavanagh et al., 2013).  These studies show that IN vaccines 
are able to reduce BRD morbidity when compared to control groups and have similar morbidity 
rates as injectable vaccines (Ellis et al., 2007) (Ellis et al., 2010, b) (Mahan et al., 2016).   
Vaccines are administered to help mitigate the effect of a pathogen, but animals may still become 
infected.  Research has shown that IN vaccines can stimulate the immune system in the face of 
maternal antibodies by stimulating local IgA (Xue 2010).  The disease sparing effect of a vaccine 
is often measured by comparing severity of disease induced by the pathogen.  Measurement of 
disease reduction include amount of virus shed nasally, lung lesion extent and severity, and rectal 
temperatures.  Studies have shown that IN vaccines were able to reduce the severity of these 
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diseases when compared to non-vaccinated calves (Vangeel et al., 2007, a).  For example, it was 
found that intranasally vaccinated calves had lower rectal temperatures and shed less virus for a 
shorter period of time (Vangeel et al., 2007, a) (Vangeel et al., 2007, b).  Disease reduction has 
also been tested between IN and injectable vaccines, finding no significant difference between 
the two groups when comparing viral shedding and rectal temperature (Ellis et al., 2013).  These 
studies suggest that IN and SC vaccines reduce disease severity similarly. 
1.7 Conclusions 
Bovine respiratory disease is a major cause of economic loss for feedlot operations.  Feedlots use 
many methods to reduce the incidence of BRD, including vaccination and metaphylactic 
antibiotics.  With increasing public awareness about antimicrobial use and resistance in the 
livestock sectors, the Canadian beef industry continues to explore ways to support antimicrobial 
stewardship, promote animal welfare, and improve economic margins for cattle producers 
through modifications in animal health management practices.  Current vaccination methods 
utilize homologous antigen presentation and administration routes.  Recently human medicine 
has begun to test heterologous antigen presentation methods of vaccination, but the cattle 
industry has little research on this topic.  The purpose of this thesis is to add to literature in this 
area, and to provide a foundation for future research regarding heterologous and IN vaccination 
in cattle. 
1.8 Objective of Research 
The overall goal of this study is to compare different calf vaccination protocols for the control of 
BRD.  To accomplish these goals two studies were performed.  The first study is outlined in 
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Chapter 2, and is a smaller scale intensive study.  The second study is outlined in Chapter 3 and 
is a larger scale commercial cow-calf vaccination field study. 
The objectives for the study in Chapter 2 are as follows: 
- Evaluation and comparison of three vaccine protocols for control of BRSV, BoHV1, 
BVDV1, and BVDV2 antibody concentrations at branding and weaning.  The lab 
techniques used for BRSV and BoHV1 will be an ELISA, while a virus neutralization 
assay will be used for BVDV1 and BVDV2.  
- Comparison of average daily gains between three vaccine protocols at important time 
points.  The important time points were determined to be birth to ‘turnout’, birth to wean, 
and birth to final (end of the study). 
These objectives were met through the enrollment of 75 calves into one of three groups.  One 
group received a homologous vaccination protocol, the second group received a heterologous 
administration route and homologous antigen presentation protocol, and the third group received 
a heterologous vaccination protocol.   
Chapter 3 is a larger scale field vaccination trial that enrolled heifer and steer calves from two 
different producers at branding.  The objectives of this study are as follows: 
- Comparison of morbidity and mortality rates between two vaccine protocols on feedlot 
calves from placement in the feedlot until the second administration of the second 
hormone implant. 
- Comparison of average daily gains between two vaccine protocols on feedlot calves from 
placement in the feedlot until the second administration of the second hormone implant. 
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Morbidity rates were determined by experienced animal health personnel and based on 
standardized and specific diagnostic criteria.  The feedlot veterinarian performed post mortem 
necropsies on animals that died to determine the cause of death.  Average daily gains were 
determined by measuring weights upon placement at the feedlot and at the time of administration 
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This chapter contains the analysis of antibody concentrations and average daily gains collected 
from beef calves from the Western Beef Development Center.  This chapter reports the 
comparison of three different vaccination protocols and comparing heterologous and 
homologous vaccination protocols.  This study also tests modified live viral vaccines for BVDV 
types 1 and 2 against inactivated viral vaccines against BVDV types 1 and 2.  This is the first 
study that compares heterologous vaccination programs for bovine respiratory disease (BRD) in 
beef cattle.  The results of this study show that heterologous vaccination protocols stimulated a 
significantly higher BRSV antibody response and had similar BoHV1 antibody concentrations as 
the homologous vaccination protocol.  The inactivated viral vaccine resulted in lower BVDV2 
23 
 
antibody concentrations than the modified live viral group.  Neither treatment group had an 
increased immune response to BVDV1, giving reason to rethink the vaccination route or timing 
of bovine viral diarrhea virus vaccination.  Further research should investigate the efficacy of 
intranasal vaccinations administered as a primer at ‘turnout’/branding, as this timing may fit 
better with cow-calf management of some herds.  Development of an intranasal BVDV type 1 
and 2 vaccine would be useful to bypass maternal antibodies, to act as a primer.  The next 
chapter compares a homologous intranasal vaccination protocol against a homologous 
injectable vaccination protocol for protection against bovine respiratory disease. 
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Bovine Respiratory disease (BRD) is an important disease syndrome in the beef cattle industry, 
causing morbidity and mortality in calves, as well as large economic losses.  Currently the most 
common vaccination protocols to protect against BRD utilize homologous modified live viral 
(MLV) vaccines.  In this study, a heterologous vaccination protocol was compared, using an 
intranasal (IN) vaccine as a primer at birth and a MLV or killed viral (KV) vaccine as a booster 
at ‘turnout’ and weaning.  Bovine viral diarrhea viruses (BVDV) type 1 and 2 were not 
vaccinated in a heterologous method as commercial IN vaccines do not contain antigens for 
BVDV types 1 or 2.  The enzyme linked immunosorbent assay (ELISA) analyses found that the 
heterologous protocol had significantly higher BRSV antibody concentrations from two weeks 
post ‘turnout’ onwards compared to the other two treatment groups, while no difference was 
observed in bovine herpes virus type 1 antibody concentrations.  Virus neutralization 
measurements for BVDV type 1 did not show an increased immune response, suggesting that 
maternal antibodies interfered with antibody induction.  The virus neutralization found that KV 
vaccines resulted in a lower BVDV2 antibody concentrations.  These results show that IN 
vaccines are important for priming the immune system in the face of maternal antibody 
concentrations, and heterologous vaccination protocols can increase antibody concentrations for 
BRSV. 
2.2 Introduction 
Bovine respiratory disease (BRD) is a complex that has a significant economic impact on 
feedlots across North America through calf mortality, lower average daily gain, and treatment 
costs (Smith, 2009) (Miles et al., 2009).  One strategy to mitigate BRD is for cow-calf producers 
to vaccinate calves to prime their immune systems for protection against BRD-associated 
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bacterial and viral pathogens.  Calves are often vaccinated against viral pathogens associated 
with BRD, including bovine respiratory syncytial virus (BRSV), bovine herpes virus type 1 
(BoHV1), parainfluenza virus 3 (PI3), and bovine viral diarrhea virus type 1 and 2 (BVDV1 and 
2) (Miles, 2009).  Bovine respiratory syncytial virus, BoHV1, and PI3 are directly associated 
with respiratory disease development, while BVDV types 1 and 2 are known to suppress the 
immune system of calves (Van Wyk, 2016) (Ridpath, 2010).  The aim of BRD vaccines is to 
promote calf health by controlling important respiratory pathogens and supporting immune 
system function. 
On cow-calf operations, injectable vaccination is one of the most common methods of 
vaccination (Waldner et al., 2018).  This type of vaccination frequently occurs at branding to 
prime the immune system, and at weaning to boost the immune system (Waldner et al., 2018).  
However, at branding calves may still have high maternal antibody (MatAb) concentrations 
which can interfere with the immune system’s ability to respond to the vaccine by masking 
antigen binding sites (Munoz-Zanzi et al., 2002) (Niewiesk, 2014).  It can be difficult to 
determine the most beneficial time to vaccinate as MatAbs wane at different rates depending on 
calf immune function and virus characteristics (Munoz-Zanzi et al., 2002) (Fulton et al., 2004).  
In recent years, mucosal vaccines have become of interest because they can bypass MatAbs and 
stimulate the calf immune system to help protect against disease.  However, optimal immune 
response depends on more than the evasion of MatAbs from vaccine priming (Mahan et al., 
2016) (Hill et al., 2012).  
Current vaccination protocols on cow-calf operations commonly utilize homologous vaccination 
(Waldner et al., 2018).  Homologous vaccination refers to priming and boosting with either the 
same type of antigen, or with the same route of administration.  This method focuses on 
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stimulating one response type from the immune system (Bolten et al., 2012) (Lu, 2009).  
Heterologous vaccination protocols, implemented in some aspects of human medicine (Lu, 2009) 
(Jung et al., 2018), utilize different routes of administration and/or present different forms of 
antigens to stimulate an increased immune response (Lu, 2009) (Jung et al., 2018).  The current 
study compares the immune responses between beef calves administered an injectable vaccine 
compared to those primed with a mucosal viral vaccine within 24 hours of birth and boosted with 
either a homologous or heterologous viral vaccine protocol at ‘turnout’ and weaning. 
2.3 Methods and Materials 
2.3.1 Animals 
Seventy-five neonatal crossbred heifer calves located at the Western Beef Development Center 
(WBDC) research facility, near Lanigan Saskatchewan, Canada, were enrolled into this study.  
This number was selected after reviewing current literature for similar studies, and consulting 
with Dr. John Ellis.  The calves selected for the study were born between late March and early 
May 2017 to cows with good udders.  The cows from this herd were annually vaccinated against 
disease due to Clostridium sps, anthrax, BRD1 and reproductive diseases prior to breeding.  At 
birth, calves were individually identified by a dangle tag and radio frequency identification 
(RFID) tag.  Calves from all groups were managed on the same pasture, and were moved as a 
group with their dams to a second pasture at ‘turnout’, and to the feedlot style pens at the 
Western Beef Development Center.  Only single birth calves born without assistance to 
multiparous dams were included in the study.     
2.3.2 Experimental Design: Randomized Clinical Control Trial 
Calves were enrolled in the study within 24 hours of birth and were observed until 60 days post-
weaning (Figure 2.1).  The calves were enrolled and randomized (Excel4 randomization formula) 
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into one of three experimental groups: injectable modified live viral (IJ-MLV) group, intranasal 
modified live viral (IN-MLV) group, and intranasal killed viral (IN-KV) group.  The IJ-MLV 
group acted as a reference group and received intranasal (IN) administration of sterile water (2 
mL) within 24 hours of birth, received a modified live viral (MLV) injectable (IJ) vaccine 
(Bovishield Gold FP5)1 at ‘turnout’, and a MLV IJ vaccine1 at weaning.  The intranasal modified 
live group (IN-MLV) received an intranasal (IN) vaccine (Inforce 3; 2 mL)2 within 24 hours of 
birth, a MLV IJ vaccine1 at ‘turnout’ (average age was 47 days, ranging from 34 – 60 days of 
age), and a MLV IJ vaccine1 at weaning (average age was 48 days, with a range of 35 to 64 days 
of age).  The intranasal killed viral group (IN-KV) received an IN vaccine (Inforce 3; 2 mL)2 
within 24 hours of birth, a killed viral (KV) vaccine (Triangle 5)3 at ‘turnout’ (average age was 





Figure 2.1. A figure showing the type of vaccination each treatment group will receive at each time point 
 
Every three calves were randomized into 1 of the 3 experimental groups based on birth order, 
and enrollment changed for every set of three calves.  At enrollment, calves were administered 
either an IN vaccine or sterile water, a 10 mL serum tube was used to collect blood samples, and 
weights were recorded in pounds, using a hanging dial scale.  Calves were administered sub-
cutaneous booster vaccinations at ‘turnout’ as per their experimental group protocol, were 
weighed, and had serum samples collected.  ‘turnout’ occurred when calves were 34-65 days old 
and involved movement from the birth pasture to a new summer pasture.  Two weeks after 
‘turnout’ serum samples were collected, and body weights were recorded.  
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At weaning calves were moved to the WBDC feedlot operation.  At this time 20 calves: 9 from 
the intranasal modified live viral (IN-MLV) group, 9 from the intranasal killed viral (IN-KV) 
group, and 2 from the injectable modified live viral (IJ-MLV) group, were removed from the 
trial to undergo a BRSV challenge study comparing homologous and heterologous vaccine 
protocols.  Less calves were removed from the IJ-MLV group, as they were treated as a sentinel 
group.  The final body weights of the remaining calves were recorded 87 days post-weaning.  At 
weaning, a subcutaneous vaccine was administered as per the experimental group protocols, 
serum samples were collected, and calves were re-weighed.  After weaning, calves were moved 
to the WBDC backgrounding pen, where groups were comingled.  Two weeks after weaning, a 
serum sample was collected, and body weight was recorded for each calf.  The calves were then 
placed in a single pen for feeding and observation of health for 60 days and a final body weight 
was collected 87 days post-weaning. The weights were collected when the calves at standard 
commercial production handling times reduce the number of movements through handling 
facilities, and to reduce stress to the animals (University of Saskatchewan’s Animal Research 
Ethics Board protocol number 20170003).  If a calf died during the trial, a necropsy was 
performed within 24 hours by a University of Saskatchewan Veterinarian to determine the cause 
of death.   
Calves were observed for BRD morbidity by experienced WBDC animal health staff and treated 
as required.  Clinical BRD disease was reported if a calf had a rectal temperature above or equal 
to 40°C (103.9 F°) and at least two of the following signs were observed: moderate depression 
(drooping head and ears), reluctance to move, tucking of the flank/abdomen, rapid shallow 




2.3.3 Test Procedures 
Serum Neutralization 
A virus neutralization assay was performed on blood samples collected at ‘turnout’, two weeks 
post ‘turnout’, weaning, and two weeks post weaning, to determine antibody concentrations for 
BVDV types 1 and 2.  Each batch consisted of a virus (BVDV1/SingerB8232) titration and 
positive (A/S calf 72) and negative (fetal calf serum) controls.  Samples were analyzed in 
duplicate.  Prior to testing, serum samples were heat inactivated at 56°C for 30 minutes.  
Samples were placed into small wells on plates for testing.  The first plate of each run utilized a 
virus back-titration to check that an appropriate virus dilution occurred.  A diluted positive and 
negative control were also included on the first plate, giving a base unit of 6.  Samples were 
diluted by use of 3-fold dilutions to determine antibody cut off values.  The virus dilution was 
added to each of the wells, and the plates were incubated at 37°C in CO2 for two hours.  A cell 
suspension was prepared with embryonic bovine tracheal cells.  The plates were removed from 
the incubator, and cells were added to each well.  The plates were sealed with tape and allowed 
to incubate at 37°C for seven days.  After the incubation period, the plates were observed for 
cytopathic effects using an inverted microscope (Waldner and Campbell, 2005). 
Enzyme-Linked Immunosorbent Assay (ELISA) 
An ELISA determined antibody concentrations on samples collected at ‘turnout’, two weeks post 
‘turnout’, weaning, and two weeks post weaning, for BRSV and BoHV1 (Durham and Hassard, 
1990) with minor modifications. Ninety-six well plates (Immulon IV) are coated with a blocking 
agent for half an hour at 37°C.  Positive, negative, and test sera are diluted 1:50 in ELISA 
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working buffer.  Control and test sera are added to duplicate well plates and incubated at 37°C 
for one hour.  After this incubation period, horseradish peroxidase conjugated protein G diluted 
in working buffer containing 4% polyethylene glycol 8000 and 0.2% gelatin solution is added to 
all wells, and incubates for an hour at 37°C.  The horseradish peroxidase enzyme reaction is 
visualized with a (2,2’-azinobis[3-ethylbenzothiazoline-6-sulfonic acid]-diammonium salt) 
substrate and the reaction is stopped with a 1% sodium dodecyl sulphate solution.   All wells 
receive 100 uL of reagents, get washed four with double distilled water containing 0.05% Tween 
20.  Antibody concentrations are reported as units derived from a calculation of the percentage of 
optical density of test wells compared to positive controls. 
2.3.4 Statistics 
Data was imported into the SPSS version 25 statistical software5.  A Shapiro-Wilk test of 
normality, with a significance value of p <0.05 was used to determine the normality of the data.  
The serum concentration data for BRSV and BoHV1 was analyzed using generalized estimating 
equations using a normal distribution, with an AR1 working correlation matrix, inputting calf as 
the repeated subject, with treatment group and time as main effects and treatment with time as an 
interaction term.  Data for BVDV1 and 2 were not normally distributed.  The serum 
concentration data for BVDV 1 and 2 was log transformed prior to analysis.  General estimating 
equations using a normal distribution with an AR1 working correlation matrix, inputting calf as 
the repeated subject, with treatment group and time as main effects and treatment with time as an 
interaction term.  A pairwise comparison was then performed to determine differences between 
groups of calves at different time points.   
Average daily gain (ADG) was calculated using weight values from birth, ‘turnout’, weaning, 
and final trial day.  Age was included in analysis when birth weights were involved.  Average 
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daily gain was analyzed using a linear regression, with treatment as a main effect, with a 
pairwise comparison between the groups to determine any significant responses between groups.  
Differences were considered significant with a p-value of <0.05. 
2.4 Results 
2.4.1 Bovine Respiratory Syncytial Virus 
At each of the four time point’s calf mean BRSV antibody concentration was calculated and 
compared (Table 2.1).  At ‘turnout’, there were no statistically significant differences between 
any of the treatment groups (p ≥ 0.9).  At two weeks post ‘turnout’, the BRSV groups antibody 
concentration for the IN-KV group were significantly higher than the IJ-MLV (p <0.01) or IN-
MLV (p = 0.03) groups (Table 2.1).  The BRSV antibody concentration for the IJ-MLV and IN-
MLV groups were not significantly different (p = 0.2).  At weaning, the IN-KV had a 
significantly higher BRSV antibody concentration than the IJ-MLV (p <0.01) or IN-MLV groups 
(p < 0.01).  The BRSV antibody concentration for the IJ-MLV and IN-MLV groups were not 
significantly different (p = 0.3).  At two weeks post weaning the BRSV concentrations for the IJ-
MLV and IN-MLV groups were not significantly different from each other (p = 0.6) and the 
antibody concentration of the IN-KV group were significantly higher than the IN-MLV (p <0.01) 
or IJ-MLV (p <0.01) groups. 
Antibody concentration differences within each group were compared between time points to 
determine whether the calves had antibody responses to the vaccinations (Figure 2.1).  Between 
‘turnout’ and two weeks post ‘turnout’, the IJ-MLV group had decreased BRSV antibody 
concentration (p = 0.02), the IN-MLV group had no significant change in antibody concentration 
(p = 0.7), and the IN-KV group had significantly increased antibody concentration (p <0.01).  
Between two weeks post ‘turnout’ and weaning, all three groups had significantly reduced BRSV 
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antibody concentration (p <0.01) (Figure 2.1).  Between weaning and two weeks post weaning, 
all three groups had significantly increased BRSV antibodies (p <0.01) (Figure 2.1). 
2.4.2 Bovine Herpes Virus 1  
At each time point, calf mean BoHV1 antibody concentrations were compared between the three 
groups (Table 2.2).  At ‘turnout’ (p = 0.7, p = 0.7, p >0.9) and at two weeks post ‘turnout’ (p = 
0.8, p = 0.5, p = 0.7), there were no statistically significant differences in BoHV1 antibody 
concentration between any of the pairwise comparisons of the groups (Table 2.2).  At weaning, 
the IN-KV group was significantly higher than the IN-MLV group (p = 0.04) (Table 2.2), and the 
IJ-MLV group was not significantly different from the IN-MLV or IN-KV groups (p = 0.1, p = 
0.7).  At two weeks post weaning there was no statistical difference between the IJ-MLV and IN-
MLV (p = 0.2), IJ-MLV and IN-KV (p = 0.6), and IN-MLV vs IN-KV (p = 0.6). 
The antibody concentration differences within group were compared between time points (Figure 
2.2).  Between ‘turnout’ and two weeks post ‘turnout’ all three treatment groups were 
significantly lower at two weeks post ‘turnout’ (p <0.1).  From two weeks post ‘turnout’ to 
weaning, all three treatment groups had significantly lower BoHV1 antibody concentration (p 
<0.1) (Figure 2.2).  Between weaning and two weeks post weaning, all three treatment groups 
had significantly increased BoHV1antibody concentration (p <0.1).  
2.4.3 Bovine Viral Diarrhea Virus 1 
The data for BVDV1 were transformed using natural logarithmic function for analysis, and 
exponentiated to compare the results.  At each of the four time points, mean BVDV1 antibody 
concentrations were calculated and compared in a pairwise manner (Table 2.3).  At ‘turnout’ and 
two weeks post ‘turnout’ the relative differences between mean BVDV1 concentrations were not 
significantly different (Table 2.3).  At weaning, the IN-KV group was significantly lower than 
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the IJ-MLV group (p = 0.01), with a relative difference of 2.1 and the IN-KV group was also 
significantly lower than the IN-MLV group (p <0.01) with a relative difference of 2.2.  The IJ-
MLV and IN-MLV groups were not significantly different from each other at weaning (p = 0.8).  
At two weeks post weaning, the IJ-MLV group and IN-MLV groups were not significantly 
different (p = 0.5); however, the IJ-MLV group was signficantly lower (p = 0.04) than the IN-
KV group, with a relative difference of 0.4.  The IN-MLV and IN-KV groups were not 
signficantly different (p = 0.1) at two weeks post weaning. 
The BVDV1 antibody concentration differences within each group were compared between the 
time points (Figure 2.3).  Between ‘turnout’ and two weeks post ‘turnout’, all three treatment 
groups had decreased BVDV1 antibody concentration levels.  Between two weeks post ‘turnout’ 
and weaning, all three groups had a decrease in BVDV1 antibody concentration levels.  From 
weaning to two weeks post weaning, the IJ-MLV and IN-MLV groups were not significantly 
different within their respective groups (p = 0.2, 0.09).  The IN-KV group had a significantly 
higher BVDV1 antibody concentration at two weeks post weaning compared to weaning (p = 
<0.01) (Figure 2.3). 
2.4.4 Bovine Viral Diarrhea Virus Type 2 
The data for BVDV2 were transformed using natural logarithmic function for analysis, and 
exponentiated to display the results.  At each of the four time points, mean BVDV2 antibody 
concentration were calculated and compared in a pairwise manner (Table 2.4).  At ‘turnout’ and 
two weeks post ‘turnout’, there was no significant differences between the three treatment groups 
(p ≥ 0.5).  At weaning, the IJ-MLV and IN-MLV groups were not signficantly different.  The IN-
KV group was signficantly lower (p <0.01) than both the IJ-MLV and IN-MLV groups by a 
relative difference of 6.0 and 9.0, respectively.  The IJ-MLV and IN-MLV groups were not 
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signficantly different (p = 0.2).  At two weeks post weaning the IJ-MLV and IN-MLV group 
were not significantly different (p = 0.2).  The IN-KV group was signficantly lower than both the 
IJ-MLV (p = 0.02) and IN-MLV (p >0.01) groups by a relative difference of 3.4 and 6.5, 
respectively. 
The BVDV2 antibody concentration differences within group were compared between the time 
points (Figure 2.4).  From ‘turnout’ to two weeks post ‘turnout’, all three treatment groups had 
significantly lower BVDV2 antibody concentrations within their respective groups.  Between 
two weeks post ‘turnout’ and weaning, all three treatment groups had a significant decrease in 
within group BVDV2 antibody concentration.  Between weaning and two weeks post weaning 
within each of the three treatment groups there was a signficant increase in BVDV2 antibody 
concentration (Figure 2.4). 
2.4.5 Average Daily Gains 
Average daily gains were calculated for calves from each group, between the important time 
points (Table 2.5).  No differences in ADG were observed between treatment groups during the 
birth to ‘turnout’ time period, IJ-MLV vs IN-MLV (p = 0.7), IJ-MLV vs IN-KV (p = 0.6), IN-
MLV vs IN-KV (p > 0.9).  From  birth to weaning  there was no significant differences observed 
between the treatment groups, IJ-MLV vs IN-MLV (p = 0.6), IJ-MLV vs IN-KV (p > 0.9), IN-
MLV vs IN-KV (p = 0.6).  The ADG from weaning to 87 days post-weaning was not 
significantly different between the treatment groups IJ-MLV vs IN-MLV (p = 0.4), IJ-MLV vs 
IN-KV (p = 0.4), IN-MLV vs IN-KV (p = 0.9). 
2.5 Discussion 
The purpose of this study was to compare the effectiveness of three vaccination protocols to 
provide increased antibody concentrations against viruses associated with BRD.  A primary 
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objective of the study was to compare heterologous and homologous vaccination protocols of 
which there is a lack of literature for beef cattle.  This study is unique in that it assessed the 
efficacy of IN vaccines as immune primers, and the effectiveness of heterologous and 
homologous vaccine protocols.  
In the beef cattle industry, pre-weaned calves most often receive a priming vaccine before 
‘turnout’/branding, while boosting vaccines are most often administered at weaning (Waldner et 
al., 2018).  A problem with vaccinating at ‘turnout’/branding is that the calves are young and 
there is a possible interference of the priming vaccine due to the presence of high maternal 
antibodies (MatAbs) (Platt et al., 2009) (Niewiesk, 2014).  The current study found that the IN 
vaccines were able to successfully prime calves when administered at birth, showing IN vaccines 
ability to bypass MatAbs.  This was observed for BRSV, as the IN-KV group had higher 
antibody concentrations at two weeks post ‘turnout’ compared to ‘turnout’, while the IN-MLV 
group had similar antibody concentrations.  The IJ-MLV group had lower antibody 
concentrations at two weeks post weaning, suggesting initial priming vaccines administered at 
‘turnout’ did not successfully stimulate the immune system.  At two weeks post ‘turnout’, the 
antibody concentrations of the IN-MLV group did not decrease significantly.  This suggests that 
the boosting was successful at stimulating an immune response or maintaining the existing 
antibody concentrations.  Based on these results, the heterologous vaccination administration did 
not show an increased antibody concentration compared to homologous administration, whereas 
heterologous antigen presentation did show a greater response than homologous antigen 
presentation.  
Interference of MatAbs occurred when priming for BVDV1, as the priming vaccine did not 
result in an increased antibody concentration, in the injectable vaccine groups, as has been shown 
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in previous studies (Ellis et al., 2001) (Downey et al., 2013).  A small difference between 
weaning and two weeks post weaning antibody concentrations was observed, indicating that the 
weaning booster vaccine did not successfully boost the calf immune system.  The IN-KV had 
significantly higher BVDV1 antibody concentrations at two weeks post weaning compared to 
weaning but was extremely low compared to ‘turnout’ and two weeks post ‘turnout’; suggesting 
a boosting response did not occur.  The age at which calves receive the priming vaccination is an 
important factor in successfully priming the immune system.  It has been shown previously that 
BVDV1 MatAb concentrations wane at a slower rate than BVDV2, BRSV, and BoHV1, 
supporting our finding that BVDV1 was the only virus to not elicit an increased immune 
response to a booster vaccine (Munoz-Zanzi et al., 2002) (Fulton et al., 2004).  As such, 
development of an IN vaccine for BVDV should be a priority, as IN vaccines are able to bypass 
MatAbs and act as a primer (Hill et al., 2012) (Woolums et al., 2013), promoting increased 
protection.   
In this study, blood serum samples were collected from calves to determine systemic (IgG) 
antibody concentrations, which were used to show the vaccine response.  Previous research has 
shown that IN vaccination has a main effect on mucosal antibody concentration levels, as well as 
increasing systemic antibody concentrations (Kavanagh et al., 2013) (Hill et al., 2012).  The 
results of this study showed the IN vaccines affected systemic BRSV antibody concentrations.  
This was seen in the IN groups, as the IN-MLV group did not have waning antibody 
concentrations two weeks after ‘turnout’, and the IN-KV group had increased antibody 
concentrations two weeks after ‘turnout’.  This provides evidence that the IN vaccines also 
primed the systemic immune system.  Antibody concentrations were analyzed to determine the 
systemic antibody response to an injectable booster.  The IN vaccines were able elicit a strong 
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mucosal response, and a minor systemic response, effectively priming the immune system (Hill 
et al., 2012) (Kavanagh et al., 2013) (Raja et al., 2018) (Jung et al., 2018).  This study has shown 
that IN vaccines can act as effective primers with increased antibody response when used in a 
heterologous vaccine protocol. 
The results of the current study show that heterologous vaccination increases BRSV antibody 
concentrations when compared to homologous vaccination.  While there is little research on 
heterologous vaccination in cattle (Walz et al., 2015), human studies have found that 
heterologous vaccination can increase protection against disease (Raja et al., 2018) (Jung et al., 
2018). Heterologous vaccination is promising for the cattle industry, but further research is 
needed to develop vaccines for heterologous prime-boosting.   
This study found that KV vaccines were not as effective in stimulating an immune response 
against BVDV2 as MLV vaccines.  These results are consistent with previous research (Dubovi 
et al., 2000) (Reber et al., 2006).  This study found that the KV vaccines had increased BVDV1 
in contrast to previous studies which found MLV vaccines elicited a greater response (Dubovi et 
al., 2000) (Reber et al., 2006) (Fulton and Burge, 2000).  The lack of difference in antibody 
concentration levels between the groups was likely due to a lack of immune stimulation.  The 
IN-KV group was significantly higher at two weeks post weaning compared to weaning (p = 
0.04), whereas the IJ-MLV (p = 0.5) and IN-MLV (p = 0.1) groups were not significantly 
different between these time points.  Heterologous vaccination was not assessed for BVDV in 
this study as the mucosal vaccine used to prime the calves did not contain antigens for BVDV 
types 1 and 2, and currently there is no commercial IN BVDV vaccine available.   
While the current study allowed the comparison of multiple different vaccination methods, one 
weakness study was in the number of vaccines each group received.  The IN groups received a 
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vaccine at birth, while the IJ-MLV group received a dose of sterile water at that time.  This could 
have influenced the overall antibody levels, through bypassing of the MatAbs and stimulating the 
immune system early (Kavanagh et al., 2013) (Hill et al., 2012).  However, if the IJ-MLV group 
was administered an IJ vaccine at birth there likely would have been no immune response as 
prior studies have shown that systemic vaccination in the face of MatAbs does not cause immune 
stimulation (Munoz-Zanzi et al., 2002).   
Alternatively, a treatment group primed with an injectable KV or MLV vaccine and boosted with 
the opposite is a possible future investigation; however, if the initial vaccination occurs at the 
traditional age of 2 – 3 months a priming response may not occur because of MatAb interference.  
Currently IN KV vaccines are not commercially available, causing KV priming to be a difficult 
and potentially fruitless effort due to MatAb interruption of IJ vaccines.   
One of the limitations of this study was the type of immune response observed.  Only humoral 
antibody concentration levels were determined, but the cell mediated immune response mounted 
by the calves were not tested.  This study shows that some mean antibody concentrations are 
higher than others; however, this does not determine level of protection against disease (Walz et 
al., 2017, 1) (Hill et al., 2012).  To observe this, a disease challenge study should be conducted, 
to determine the disease sparing effect of the vaccine protocol (Ellis et al., 2018).  Without doing 
a challenge study, a large field study using naturally occurring disease is an option for future 
studies.  In future research, it would be important to determine different methods of applying 
heterologous vaccinations, changing the order that different antigens are applied to the animals.  
Development of IN vaccines for BVDV types 1 and 2 would be useful to provide protection in 
the face of MatAbs, as research has shown that IN vaccination against BVDV increase protection 
of calves, compared to control calves (Xue et al., 2010). 
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Prime-boost vaccination has become the standard for many producers (Waldner et al., 2018), and 
this study tests different possible methods to improve the effectiveness of prime-boosting.  
Heterologous antigen presentation is one such method and resulted in a greater antibody 
concentration response against BRSV compared to the homologous antigen presentation groups.  
Homologous route of administration did show some effect, as the antibody concentrations 
against BRSV of the IN-MLV group did not significantly decrease between two weeks post 
‘turnout’ and ‘turnout’ where the IJ-MLV group did.  This provides evidence that the vaccination 











Table 2.1. A comparison of the mean difference of BRSV antibody concentration between groups at each 
of the different time points. 
 
Mean Difference of BRSV Antibody 
Concentrations p-value 




















0.6 -0.3 0.3 
0.9 0.9 >0.9 




-6.0 19.0 13.0 
0.2 <0.01 0.03 
(-15.7 , 3.8) (8.6 , 29.3) (1.4 , 24.6) 
Weaning 
1.1 13.3 14.4 
0.3 <0.01 <0.01 




3.3 94.9 98.1 
0.6 <0.01 <0.01 
(-9.1 , 15.6) (81.3 , 108.5) (85.3 , 111.0) 
 
 
Table 2.2. A comparison of the mean difference of BoHV1 antibody concentrations between groups at 
each of the different time points. 
 
Mean Difference of BoHV1 Antibody 
Concentrations p-value 















       
‘Turnout’ 
-1.7 1.8 0.1 
0.7 0.7 >0.9 




-1.2 2.7 1.5 
0.8 0.5 0.7 
(-9.2 , 6.7) (-5.0 , 10.5) (-7.0 , 9.9) 
Weaning 
0.2 1.1 1.3 
0.7 0.1 0.04 




-4.3 1.9 -2.4 
0.2 0.6 0.6 




Table 2.3. A comparison of the relative difference of BVDV1 antibody concentrations between groups at 
each of the different time points. 
 
Relative Difference of BVDV1 Antibody 
Concentrations p –value 
















1.0 1.5 1.6 
0.9 0.2 0.2 




1.0 1.2 1.1 
0.9 0.6 0.7 
(0.6 , 2.0) (0.6 , 2.2) (0.7 , 2.0) 
Weaning 
1.0 2.1 2.2 
0.8 0.01 <0.01 




0.8 0.4 0.5 
0.5 0.04 0.1 
(0.3 , 1.8) (0.2 , 1.0) (0.2 , 1.2) 
 
 
Table 2.4. A comparison of the relative difference of BVDV2 antibody concentrations between groups at 
each of the different time points. 
 
Relative Difference of BVDV2 Antibody 
Concentrations p-value 
















1.09 1.1 1.01 
0.8 0.7 >0.9 




1.0 0.8 0.8 
0.9 0.5 0.5 
(0.6 , 1.6) (0.5 , 1.4) (0.5 , 1.5) 
Weaning 
0.7 6.0 9.0 
0.4 <0.01 <0.01 




0.5 3.4 6.5 
0.2 0.02 <0.01 












Contrast (CI 95%) 
Treatment Treatment Treatment 


















1.0 1.0 1.0 
-0.0.39 -0.047 -0.0082 
0.7 0.6 >0.9 
(-0.25 , 0.17) (-0.25 , 0.16) (-0.21 , 0.20) 
Birth to 
Wean 
1.1 1.1 1.1 
-0.041 -0.0049 0.036 
0.6 >0.9 0.6 
(-0.18 , 0.010) (-0.14 , 0.13) (-0.10 , 0.18) 
Birth to 
Final 
0.9 0.9 0.9 
-0.055 -0.052 0.0024 
0.4 0.4 0.9 







Fig. 2.2. A comparison of mean BRSV antibody concentrations within a treatment group at different time 
points 
*a b c d denote significant differences between time points for the IJ-MLV group. 
*e f g denote significant differences between time points for the IN-MLV group. 
*h i j k denote significant differences between time points for the IN-KV group. 
*IJ-MLV group received an injectable MLV vaccine at ‘turnout’ and weaning.  The IN-MLV group 
received an IN MLV vaccine within 24 hours of birth, and a MLV injectable vaccine at ‘turnout’ and 
weaning.  The IN-KV group received an IN MLV vaccine at birth, and a KV injectable vaccine at 









Fig. 2.3. A comparison of mean BoHV1 antibody concentrations within a treatment group at different 
time points 
*a b c denote significant differences between time points for the IJ-MLV group. 
*d e f denote significant differences between time points for the IN-MLV group. 
*g h i denote significant differences between time points for the IN-KV group. 
*IJ-MLV group received an injectable MLV vaccine at ‘turnout’ and weaning.  The IN-MLV group 
received an IN MLV vaccine within 24 hours of birth, and a MLV injectable vaccine at ‘turnout’ and 
weaning.  The IN-KV group received an IN MLV vaccine at birth, and a KV injectable vaccine at 











Fig. 2.4. A comparison of mean BVDV1 antibody concentrations within a treatment group at different 
time points 
*a b c denote significant differences between time points for the IJ-MLV group. 
*d e f denote significant differences between time points for the IN-MLV group. 
*g h i j denote significant differences between time points for the IN-KV group. 
*IJ-MLV group received an injectable MLV vaccine at ‘turnout’ and weaning.   
The IN-MLV group received an IN MLV vaccine within 24 hours of birth, and a MLV injectable vaccine 
at ‘turnout’ and weaning.  The IN-KV group received an IN MLV vaccine at birth, and a KV injectable 











Fig. 2.5. A comparison of mean BVDV2 antibody concentrations within a treatment group at different 
time points 
*a b c d denote significant differences between time points for the IJ-MLV group. 
*e f g denote significant differences between time points for the IN-MLV group. 
*h i j k denote significant differences between time points for the IN-KV group. 
*IJ-MLV group received an injectable MLV vaccine at ‘turnout’ and weaning.  The IN-MLV group 
received an IN MLV vaccine within 24 hours of birth, and a MLV injectable vaccine at ‘turnout’ and 
weaning.  The IN-KV group received an IN MLV vaccine at birth, and a KV injectable vaccine at 
‘turnout’ and weaning. 
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This chapter contains the analysis of data collected from field study trial conducted at a 
commercial cow-calf operation.  This chapter represents a larger-scale field study to test the 
effectiveness of intranasal vaccines (IN) in reducing morbidity and mortality of bovine 
respiratory disease complex (BRD), and the effects the vaccination protocol has on average 
daily gain (ADG).  Small scale disease challenge studies have been conducted with the results 
showing that IN vaccines can successfully prime the immune system (Xue et al., 2010) (Vangeel 
et al., 2009).  The results of this chapter revealed that the control group, which received an 
injectable (IJ) vaccine, and the IN group did not have significant differences between morbidity, 
mortality, and ADG.  Further research regarding heterologous vaccination would be beneficial, 
as this and most other research is performed using a homologous vaccination protocol.   





Bovine respiratory disease (BRD) is important cause of morbidity, mortality and economic loss 
in beef production.  Bovine respiratory disease has its greatest impact on lightweight calves due 
to weaning stress, mixing of source groups at auction marts and feedlot arrival, and 
transportation; all of which may occur in a short temporal window.  This research project 
compares intranasal (IN) and injectable (IJ) modified live viral (MLV) vaccines as primers for 
BRD disease-related antibody production.  Calves were randomly enrolled at branding into one 
of two experimental groups: IN or IJ.  Both groups received a subcutaneous MLV vaccine at 
weaning.  From weaning to 60 days post weaning, animal health data (morbidity, mortality) were 
collected, and calf body weights were recorded during standard production handling time points.  
Morbidity, mortality, and ADG were compared between vaccination groups while controlling for 
the effect of gender, feedlot pen, and farm pasture.  The results showed that morbidity, mortality, 
and ADG were similar between vaccine groups and between genders (p≥0.05).  These results 
suggest that both IN and IJ vaccines stimulate the immune system against BRD.  This study was 
limited in its power to detect differences in mortality and therefore differences that are clinically 
significant may not be statistically significant.  Mortality for the IN-MLV group had a strong 
numerical difference of 1.6% as compared to the IJ-MLV group with 0.3% from weaning to 60 
days post weaning. 
3.2 Introduction 
Bovine respiratory disease (BRD) is an important causes of production losses in all aspects of the 
cattle industry (Waldner et al., 2018).  Bovine respiratory disease results in large economic 
losses for the producer through cost of treatment, reduction in feed efficiency, loss in carcass 
value, and death losses (Cernicchiao et al., 2013) (Smith 2009).  Research has found that BRD 
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morbidity is 16% on average across feedlots in the United States, with mortality ranging from 
1.0 to 1.75% on average, depending on calf age (Aphis.usda.gov, 2013, b) (Miles et al., 2009).   
Bovine respiratory disease is thought to be initiated by 1 or more viral infections that 
compromise the calf’s immune system; allowing a secondary bacterial infection to occur 
(Panciera and Confer, 2010).  Five viruses commonly associated with BRD include: bovine 
respiratory syncytial virus (BRSV), bovine herpes virus type 1 (BoHV1), parainfluenza 3 (PI3), 
and bovine viral diarrhea virus types 1 and 2 (BVDV1, BVDV2) (Miles, 2009) (Ridpath, 2010) 
(Jones, Chowdhury, 2010).  The three viruses directly related to BRD are BRSV, BoHV1, PI3 
(Miles, 2009).  Bovine viral diarrhea virus type 1 and type 2 is not often viewed as a cause BRD, 
but rather suppresses the calf’s immune system, allowing other pathogen infections to occur 
(Ridpath, 2010).  Vaccination is an important method of controlling these viruses (Wildman et 
al., 2008).      
Vaccination presents antigens of one or more pathogens to a host’s immune system, without 
causing disease in the animal.  After vaccination, the immune system develops memory cells, 
allowing a more rapid and powerful immune response when future, similar pathogen exposure 
occurs.  Research has shown the best vaccination method to increase resistance against a virus is 
through a prime-boost vaccination method (Kardani et al., 2016) (Lu, 2009).  This method 
consists of administering an initial vaccine (primer) followed by a second vaccine (booster).  
Commonly the prime-boost method is accomplished using an injectable modified live viral 
(MLV) vaccine for both the primer and the booster (Waldner et al., 2018).  A problem that can 
occur with this protocol is failure of the priming vaccine to successfully stimulate the immune 
system due to interference from maternal antibodies (Munoz-Zanzi et al., 2002) (Platt et al., 
2009) (Niewiesk, 2014), resulting in a poor immune response and leaving the calf susceptible to 
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disease.  Intranasal (IN) vaccines have been shown to bypass maternal antibodies, allowing them 
to act as effective primers for the immune system (Xue et al., 2010) (Walz et al., 2017, 1) 
(Vangeel et al., 2009).  Intranasal (IN) vaccines have been shown to offer similar protection 
against disease as injectable vaccines (Ellis et al., 2007) (Ellis et al., 2010, 2) (Mahan et al., 
2016).   
The current study compares the effectiveness of an intranasal MLV vaccine priming to an 
injectable MLV vaccine priming for protection against BRD.  Effectiveness of the vaccine 
protocol will be determined through analyses of morbidity and mortality due to BRD, and 
average daily gains. 
3.3 Materials and Methods 
3.3.1 Animals 
Privately owned crossbred commercial beef calves born to multiparous dams were sourced from 
two producers, designated Farm #1 and Farm #2, located in Saskatchewan, Canada.  Calves at both 
farms were identified with a unique numbered dangle tag and a radio frequency identification 
(RFID) tag.  
3.3.2 Randomized Controlled Trial 
At branding, one to three months of age, calves were allocated into either the IJ-MLV group, or 
the IN-MLV group by systematic sampling, stratified by pasture.  This was accomplished by 
flipping a coin at the start of the day to determine the order of group enrollment.  When the coin 
flip was heads, the calves were enrolled in the order of one IJ-MLV group calf, then one IN-MLV 
group repeated until all calves from the pasture were enrolled.  When the coin flip was tails, the 
calves were enrolled in the order of one IN-MLV group calf, then one IJ-MLV group calf, repeated 
until all calves on the field were enrolled. From Farm #1, 645 calves were enrolled into the two 
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groups at branding, which occurred in late June of 2017.  At branding calves received a BRD 
vaccine (Bovishield Gold FP51, Inforce 32), a multivalent Clostridium sps. vaccine3, and a non-
steroidal anti-inflammatory4.  Calves were managed extensively on 7 pastures, with staff regularly 
checking calves for signs of disease.  Calves were weaned in late September of 2017 and moved 
to a nearby feedlot. The treatment groups were commingled and housed in four pens by gender 
after moving to the feedlot.  At weaning, the IJ-MLV group had 163 steers and 155 heifers, while 
the IN-MLV group had 169 steers and 150 heifers.  Upon arrival at the feedlot, calves were 
processed and received a booster vaccine (Bovishield Gold One Shot5), a growth implant6, a 
multivalent Clostridium sps. booster vaccine3, and a metaphylactic antibiotic7.  In the feedlot pens, 
study calves were comingled with non-trial calves, sourced from the same producer.  The number 
of calves from each treatment group were similar within each of the pens (Table 3.1).   
From Farm #2, 240 calves were enrolled in the IJ-MLV group, and 241 calves were enrolled in 
the IN-MLV group.  Calves were randomly enrolled at branding, which occurred in Mid-August 
of 2017.  Calves from Farm #2 were castrated at branding and received a dose of a nonsteroidal 
anti-inflammatory drug4.  Calves were managed extensively on 3 pastures, with experienced 
animal health staff blinded to the treatment groups regularly checking calves for signs of disease.  
Calves were shipped to a feedlot approximately 80 kilometers away in the mid November, 2017.  
Due to the cattle market at the time, only the steers were shipped to the feedlot.  The steers were 
separated into two pens, comingling with calves from auction marts at the feedlot. 
3.3.3 Sample and Data Collection 
Calves were monitored on a weekly basis by ranch staff for signs of BRD when on pasture and 
daily after weaning.  Bovine respiratory disease cases were defined as calves that had a rectal 
temperature above or equal to 40°C (103.9 F°) as well as at least two of the following signs: 
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moderate depression (drooping head and ears), reluctance to move, tucking of the 
flank/abdomen, rapid shallow breathing, or increased respiratory effort.  If a calf met the BRD 
case definition criteria, the calf was treated by feedlot staff and morbidity data were recorded. 
All calves that died in the feedlot had a necropsy performed and digital photographs recorded 
within 24 hours to determine cause of death.  Standard digital photographs and clinical history 
were provided to the blinded consulting veterinarian and cause of death was established for each 
animal.  All causes of mortality were recorded; however only BRD mortality was included in the 
data analysis.  Body weights were collected at two time-points for calculation of ADG; weights 
were collected upon arrival at the feedlot and at reapplication of a growth promoting implant, 
averaging 68 days on feed, ranging from 52 to 73 days. 
3.3.4 Statistics 
Statistical analyses were conducted using STATA Version 15.  Post weaning mortality and 
morbidity were analyzed using a generalized linear mixed model equation with a logit link 
function and binomial distribution.  Vaccine and gender were independent variables, while pen 
and pasture were included as random effects variables.   
Average daily gain was determined from weights recorded at arrival to feedlot and reapplication 
of a growth promoting implant.  The dates when weights were collected varied depending on the 
pasture and pen, and this is accounted for in the statistical calculations.  The ADG results were 
analyzed using a multi-level mixed effects generalized linear model, using a normal distribution.  
Vaccine and gender were independent variables, while pen and pasture were included as random 




3.4.1 Group Information 
Farm #2 was originally planned to background all 480 calves, but due to feed prices, the producer 
sold the calves in mid-November.  We were able to retain 196 steers sold to the same feedlot as 
calves from Farm #1. However, the calves from Farm #2 were not included in analysis because 
the calves were raised differently from the calves on farm #1, and the total calf numbers were too 
low for a useful independent analysis to occur.    
3.4.2 Average Daily Gain 
Average daily gain was compared between the treatment group or gender (Table 3.3).  Neither 
the vaccine group (p = 0.8) nor gender (p >0.9) were significant factors in determining ADG of 
calves.  This shows that ADG was not impacted by the vaccine protocol in this study. 
3.4.3 Morbidity Due to Bovine Respiratory Disease 
Morbidity due to BRD was compared by treatment group or gender.  No significant difference (p 
= 0.7) was seen between the treatment groups (Table 3.2).  Gender was not a significant factor in 
determining difference between morbidity due to BRD (Table 3.2).  
3.4.4 Mortality Due to Bovine Respiratory Disease 
Mortality due to BRD was compared by treatment group or gender.  No significant difference (p 
= 0.1) was observed between the treatment groups, though a large numerical absolute difference 
was found; injectable 0.3% (1) vs intranasal 1.6% (5) (Table 3.2).  Gender was not associated 




This study did not show a difference between the IN and IJ priming vaccines related to ADG.  In 
the current study it is difficult to determine if the lack of difference in ADG was caused by 
vaccine success/failure, lack of disease pressure or reduced power in the study.  To understand 
whether the vaccines successfully protected the animal from disease, antibody concentrations 
and lung lesion scores would have been useful parameters to measure, as was done in previous 
field studies (Ollivett et al., 2018) (Cavirani et al., 2016).  These parameters allow researchers to 
more accurately identify respiratory disease in calves (both clinical and sub-clinical disease) 
(Forbes et al., 2004).  This study found that ADG was not different between the IJ and IN 
groups, which agrees with previous research (Ollivett et al., 2018).  
While this study did not measure disease severity, it has been shown in previous studies that IN 
and IJ vaccines can reduce the severity of disease similarly (Vangeel et al., 2007) (Ellis et al., 
2010, b).  A reduction in disease severity is beneficial to the producer, as it decreases the time 
calves spend in sick pens, the number of treatments, and the number of days the calf is on feed 
(Smith, 2009) (Cernicchiaro et al., 2013).  However, vaccination does not guarantee protection to 
calves.  Research in veal calves found that IN vaccines did not have significantly different 
morbidity or mortality rates between the IN and non-vaccinated groups (Cavirani et al., 2016).  
This provides evidence that calves with maternal antibodies do not gain a disease sparing effect 
due to IN vaccination over unvaccinated calves, however, the use of IN vaccine for immune 
stimulation in calves that have maternal antibodies could be important for protecting calves after 
the maternal antibodies have waned (Ellis et al., 2013), or as a primer for a booster vaccine (Hill 
et al., 2012). While disease severity was not determined in this study, it has been done in other 
field studies (Ollivett et al., 2018), using ultrasounds to determine the level of lung consolidation 
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in calves.  This could be used to help determine the disease reduction each vaccine provides 
however it is not practical on commercial operations (Ollivett et al., 2018).  While disease 
severity of each treatment group could not be determined, the study was able to compare 
important production parameters; morbidity, mortality, and average daily gain of the different 
study groups.  
It has been shown previously that male calves have higher ADG and are more susceptible to 
BRD than heifers (Snowder et al., 2006).  However, in this study no difference was found in 
ADG, or in morbidity, or mortality rates.  Steers and heifers were housed in separate pens, 
comingling both experimental groups together, as well as comingling calves that were not on 
trial.  These factors could have an impact on why no differences were observed between the 
genders.  Part of the reason that no differences were seen could be due to vaccination protocols 
within the pen and calves being from a single source.  These factors could promote herd 
immunity within the pen, leading to low disease pressure, causing a lack of difference between 
groups.  
In this study, only 6 mortalities due to BRD, roughly 1%, were observed.  The mortality rate due 
to BRD in feedlots has been observed to be between 1 and 2% depending on the risk group 
(Miles et al., 2009) (Engler et al., 2014), putting this trial on the lower end of average.  The 
calves used in this chapter were relatively low risk, coming from a single producer.  Of the 6 
deaths, 1 was in the IJ group, and 5 were in the IN group.  This difference was not significant (p 
= 0.1) but may be clinically important.  To gain appropriate power (0.8) to determine if the 
mortality was significantly different, the IN-MLV and IJ-MLV groups would require 1021 
calves each, given the mortality observed in this study.  This information suggests that while a 
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difference was not seen in this trial, the vaccination protocol could have an impact on calf 
mortality.  
Due to changes in beef calf market conditions the producer from farm #2 sold all enrolled heifer 
calves to a feedlot and we were unable to track them.  Due to potential differences between 
heifers and steers, gender was accounted for in this study to analyze morbidity, mortality, and 
ADG.  The use of both steers and heifers allowed us to observe how the different vaccine 
protocols affected the different gender of calves, as previous research has shown gender has an 
effect on ADG and morbidity (Cernicchiaro et al., 2012) (Snowder et al., 2006).  The numbers of 
heifers and steers were similar between the IN-MLV and IJ-MLV groups, with the IJ-MLV 
group having 155 heifers and 163 steers and the IN-MLV group having 150 heifers and 169 
steers.   
The current study compared two homologous methods of antigen presentation in the vaccine 
protocol, as both were MLV vaccines.  In human medicine, heterologous vaccination has been 
researched and used in practice as it has been shown to offer increased immune response (Bolton 
et al., 2012).  Currently the cattle industry does not use heterologous vaccination methods, rather 
priming and boosting with the same vaccine type.  Research conducted in Chapter 2 compared 
heterologous and homologous vaccination protocols for antibody concentrations against BRD, 
showing heterologous vaccination can increase antibody concentrations for BRSV.  This is an 






Table 3.1. Number of calves from each treatment allocated to each pen upon placement at the feedlot.  
Pen #1 and #2 contained only steers, and pen #3 and #4 contained only heifers. 
  Number of Calves 
  Pen 1 Pen 2 Pen 3 Pen 4 Total 
Injectable 75 88 67 88 318 
Intranasal 78 91 61 89 319 
 
Table 3.2. Comparison of BRD morbidity, mortality, and ADG between treatment groups after placement 
at the feedlot until re-implantation.  Treatment Groups are further subdivided by gender and combined. 
  Injectable Intranasal 
  Steer Heifer Combined Steer Heifer Combined 
BRD Morbidity 18 (11%) 11 (7%) 29 (9%) 19 (11%) 13 (9%) 32 (10%) 
BRD Mortality 1 (0.6%) 0 (0.0%) 1 (0.3%) 3 (1.8%) 2 (1.3%) 5 (1.6%) 
ADG (kg/day) 1.6 1.6 1.6 1.6 1.6 1.6 
 










Gender 0.0090 -0.6 0.6 >0.9 
Vaccine 0.016 -0.1 0.1 0.8 
For comparisons, the group used as the basis for comparison for gender was the steer group, and for 
vaccine was the injectable vaccine group. 
Table 3.4. The effect of gender and vaccine on BRD Morbidity and Mortality 





Post Wean BRD 
Morbidity 
Gender 0.84 0.3 2.9 0.8 
Vaccine 1.11 0.7 1.9 0.7 
Post Wean BRD 
Mortality 
Gender 0.54 0.1 5.9 0.6 
Vaccine 5.16 0.6 45.2 0.1 
For comparisons, the group used as the basis for comparison for gender was the steer group, and for 
vaccine was the injectable vaccine group. 
 
3.7 Endnotes 
1Bovi-Shield Gold FP5, Zoetis, Kirkland, Quebec 
2Inforce 3, Zoetis, Kirkland, Quebec 
3Ultrabac 7, Zoetis, Kirkland, Quebec 
4Meloxicam, Apotex Inc., Toronto, Ontario 
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5Bovi-Shield Gold One Shot, Zoetis, Kirkland, Quebec 
6Revalor-G, Merck Animal Health, Kirkland, Quebec 






The overarching research objectives of this thesis were to test the effectiveness of IN vaccines as 
primers to protect calves from BRD and compare homologous and heterologous vaccination 
protocols.  To achieve these objectives two separate studies were conducted.  Chapter 2 tests the 
effectiveness of a MLV IN vaccine primer given at birth, boosted with an IJ-MLV or KV 
vaccine at ‘turnout’ and weaning.  These two protocols are compared to a standard protocol 
using an IJ-MLV primer at ‘turnout’, and an IJ-MLV booster at weaning.  The effectiveness of 
the vaccine protocols was determined through antibody concentrations comparisons and ADG.  
An ELISA was used to determine the antibody concentrations for BRSV and BoHV1, and a virus 
neutralization was performed for BVDV types 1 and 2.  Chapter 3 was a large-scale field study 
conducted to determine the effectiveness of IN vaccines as a primer compared to IJ vaccination.  
The effectiveness of the vaccine protocols was compared by measuring the difference in 
morbidity, mortality, and ADG.   
4.2 General Discussion 
The information in the two chapters add new information to the literature, filling in gaps of 
knowledge regarding vaccination for BRD in beef cattle.  The majority of studies focusing on IN 
vaccines have been small scale challenge studies or lab studies (Ellis et al., 2007) (Ellis et al., 
2010) (Vangeel et al., 2009) (Hill et al., 2012).  Chapter 2 is a smaller scale study, having 75 
animals and performing tests to determine antibody levels, to help determine the effectiveness of 
different vaccine protocols.  It differentiates itself by comparing heterologous methods of 
vaccination to homologous methods.  A small number of large-scale field studies have been 
conducted testing IN vaccines on veal and dairy calves (Cavirani et al., 2016) (Ollivett et al., 
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2018).  Chapter 3 is a larger scale field trial, which is rarely done using extensively managed 
beef cow-calf commercial operations, and it compares IN priming vaccines against IJ priming 
vaccines in calves destined for a feedlot.  These studies are important to assist producers and 
veterinarians in choosing a proper vaccination protocol.   
It has been well documented that IN vaccines are effective at providing calves protection when 
compared to non-vaccinated calves (Ellis et al., 2010) (Ellis et al., 2007) (Vangeel et al., 2007) 
(Vangeel et al., 2009).  Intranasal vaccines have also been shown to effectively prime a calf’s 
immune system in the face of maternal antibodies (Hill et al., 2012) (Ellis et al., 2013).  Chapter 
2 adds to this area of literature, by presenting a unique study through the inclusion of 
heterologous vaccination.  Heterologous vaccination has been researched in human medicine 
(Lu, 2009) (Jung et al., 2018), and in beef cattle when focusing on reproductive disease (Walz et 
al., 2015).  This study observes the effect of heterologous vaccination on BRD. Both chapter 2 
and 3 agree that heterologous vaccination route did not increase immune stimulation above that 
of the homologous vaccination route.  As for heterologous antigen presentation (MLV and KV), 
an increase in antibody concentrations for BRSV was observed in Chapter 2.  This creates 
opportunities for further studies, as the order or vaccination could be important in obtaining the 
greatest level of protection against disease.   
Clinical disease scores and morbidity are frequently used to determine the effectiveness of 
vaccines (Ellis et al., 2010, b) (Ellis et al., 2007) (Ollivett et al., 2018).  If a calf is successfully 
vaccinated, its immune system will be prepared to respond to natural exposure of the disease.  
When the immune system responds rapidly, the virus has less chance of replicating in the host 
and causing illness.  In both chapters 2 and 3, the IN and IJ vaccination groups had similar 
morbidity rates.  Chapter 2 showed that both IN and IJ vaccines elicit a similar immune response 
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to BRSV and BoHV1, when homologous antigen presentation is used.  Chapter 3 found that IN 
and IJ vaccine primers resulted in a similar morbidity rate when calves were placed in a feedlot 
setting.  These results agree with previous research, which has found that both vaccine types can 
elicit a similar immune response/protection (Ellis et al., 2013) (Vangeel et al., 2007) (Hill et al., 
2012). 
Mortality is an important parameter when studying BRD.  In Chapter 2 mortality was not 
significantly different between the IN and IJ vaccine groups, however in Chapter 3 a numerical 
difference was seen, with the p-value trending towards significance.  These results agree with 
previous studies that have found similar results; however, the studies are often challenge studies 
and are not directly comparable to a field study (Ellis et al., 2010) (Vangeel et al., 2009) (Ellis et 
al., 2007).  One reason that challenge studies are used is because they require a lower number of 
animals to see a difference in the morbidity and mortality of different groups.  In Chapter 3, a 
larger population was used, compared to the aforementioned challenge studies.  The mortality 
was trending towards significant in Chapter 3, and if a larger population size had been used, a 
significant difference may have been observed.  
In both experimental chapters of this thesis, ADG was observed, to assess differences between 
vaccination protocols.  Average daily gain is an important economic factor for producers.  
Average daily gain can be influenced by several factors such as: morbidity, genetics, pen 
condition, weather, and feed consumed (Belasco et al., 2015).  Genetics and weather are factors 
that a feedlot will have difficulty manipulating in a given population of animals, but morbidity is 
one that can be manipulated and improved through vaccination, and the ability of vaccines to 
control disease and sub clinical disease could result in an increased ADG (Forbes et al., 2004).  
Throughout the studies in Chapters 2 and 3, no significant difference was observed in ADG.  
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However, a small numerical difference was seen between the ADG in the groups, suggesting that 
further research in vaccine strategies may be of worth to cattle producers.   
While differences in vaccination protocols were seen throughout these studies, the way a 
producer manages their cattle will have an impact on the protocol that they use.  The important 
benefit to IN vaccines is their ability to bypass maternal antibodies (Ellis et al., 2013).  If a 
producer vaccinates their calves after maternal antibodies have waned (3-4 months after birth), 
then an IJ vaccine may be more effective as it contains antigens against BVDV types 1 and 2, 
whereas commercial IN vaccines do not (Downy et al., 2013) (Fulton et al., 2004).  When 
choosing a vaccination protocol, the type of diseases that are most common or most impactful to 
the producer should be considered.  For example, if a producer frequently had BRSV-related 
respiratory disease diagnosed in calves, they may consider a heterologous method, as the study in 
Chapter 2 showed the heterologous group had higher antibody concentrations against BRSV.  
Producers should also consider their handling facilities when choosing a vaccination protocol.  If 
a producer does not restrain the calves head appropriately, it can be more difficult to properly 
administer IN vaccines compared to IJ vaccines, due to the freedom of movement the calf’s 
head.  However, with the use of a calf tipping table or ropes, IN vaccines may be just as easy to 
administer as IJ vaccines.  These are a few factors that should be considered while a producer is 
deciding on a vaccination protocol for their cattle. 
The two studies performed in this thesis build upon the knowledge of each other.  Chapter 3 was 
effective in showing that in a commercial calf production system, IN and IJ vaccines offer 
similar protection against BRD in a feedlot.  Chapter 2 was beneficial as it allowed us to measure 
the effects that the different vaccination protocols had on the immune systems of the calves.  
Chapter 2 helps explain why the results in Chapter 3 may have occurred.  Providing vaccination 
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at birth helps determine if IN vaccines could effectively bypass maternal antibodies, act as an 
effective primer, and provide increased immune stimulation over calves not vaccinated at birth.  
This research shows that IN vaccines successfully prime the immune system, even in the face of 
maternal antibodies.  It also shows that prime-boosting with heterologous antigen presentation 
can be beneficial depending on the virus.   
While the studies in Chapter 2 and Chapter 3 were successful and answered important questions, 
there were limitations to the studies.  Chapter 2 was a smaller scale laboratory-based study, 
focusing on the immune responses of calves to different vaccination protocols.  One limitation of 
this study was the type of sample collected.  It has been shown in previous studies that IN 
vaccines elicit a mucosal response while IJ vaccines elicit a systemic response.  The tests 
conducted only measured systemic immune responses, minimizing the results of the IN vaccines. 
Previous research has clearly shown a mucosal immune response to IN vaccination in cattle (Hill 
et al., 2012).  The type of tests used also minimized the immune response BoHV1 may have had, 
since BoHV1 vaccination results in a strong CMI compared to the IgG response.  Using multiple 
tests to measure all immune responses would have been ideal, however the cost to run all the 
tests outweighed the benefit for this project.  While exact differences between all immune 
response measures weren’t tested, a general idea of immune response trend was observed.  
Another limitation of this study was the outcome measure itself.  Using antibody concentrations 
is a useful way to determine if an immune response is different between vaccination groups.  The 
limitation is that antibody concentration does not directly translate to disease protection.  While 
it is good to know that antibody differences occur, without knowing how they impact BRD 
morbidity, antibody concentration do not always reflect clinical differences and this is why larger 
scale field trials, such as that in Chapter 3, are needed.   
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Chapter 3 was a larger scale field study, observing morbidity, mortality and average daily gains.  
One limitation to this study was the use of commercial herds and this presents a challenge 
because it is difficult to monitor the management of the herds. While using commercial herds is a 
limitation, it is also one of the most important benefits of this trial because it allowed the 
comparison of vaccine protocols in a ‘real world’ situation.  The difficulty in managing these 
larger cow-calf field trials is why they are rarely done, but this makes this trial very unique and 
will provide useful information to producers and veterinarians.  An important example of this 
limitation is with Farm #2, which had calves that were born and branded later than Farm #1, so 
they were too different to be analyzed together, as well as being sold where they could not be 
followed.  Another limitation of a larger scale field trial is related to measurement of disease.  
While morbidity and mortality were able to be measured, it was difficult to be sure that every 
animal showing signs of respiratory disease was identified due to the non-specific means of BRD 
identification used here and commonly in commercial production. Also, there were losses of 
calves that occurred without post mortem diagnosis. Cause of death on pasture was difficult to 
determine because the calves were often severely scavenged when they were found, and some 
carcasses were not found at all. However, the available data will help veterinarians better 
understand the effectiveness of vaccines on commercial cattle. One limitation of the commercial 
feedlot setting was mixing of trial calves with non-trial calves in the pens; mixing of calves from 
outside the trial may have provided a greater disease challenge, however there was no way to 
insure the level of challenge was the same in each pen.    
This study has shown that heterologous vaccination is an effective method for the control of 
BRD.  Chapter 2 outlines the need to consider more than one type of immune response, and the 
need of larger scale field studies.  Future studies should measure not only IgG immune 
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responses, but also IgA when using IN vaccines, or CMI when measuring BoHV1 immune 
responses.  Antibody concentrations are useful for preliminary studies, but do not translate into 
disease control.  Larger scale field studies are important in determining disease control 
capabilities of vaccines, as they can measure morbidity and mortality in natural environments.  
Currently larger scale cow-calf field studies are not common, due to the cost and potential 
challenges.  Future research should focus on the use of heterologous vaccination protocols in 
larger scale field studies, to get a better understanding of how these protocols can impact 
morbidity, mortality, and average daily gain. 
Chapter 2 showed that the response to vaccine antigen for BVDV types 1 and 2 in the face of 
maternal antibodies was poor. The poor priming response in young calves should be further 
investigated to find a better method of priming calves in the face of maternal antibodies.  One 
approach would be the use of BVDV antigens mucosally in the face of maternal antibodies rather 
than using an injectable presentation of the antigen.  This work should also observe the 
difference in heterologous vs homologous boosting. 
4.3 General Conclusions 
The results of these two studies provide important information for producers, veterinarians, and 
researchers, through the introduction of a new type of vaccination program to BRD; heterologous 
vaccination.  It confirms that IN vaccinations can have a similar effect on animal health as 
injectable vaccines, and that heterologous vaccination protocols can be beneficial over 
homologous vaccination protocols in some cases. 
Throughout the two studies, IN-MLV vaccines were delivered as the priming vaccines in the test 
groups, while injectable vaccines were delivered as the priming vaccine in the control groups.  
The two chapters of this thesis agreed that IN vaccines were able to successfully prime the 
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immune system, similar to that of IJ vaccines.  In Chapter 2, the IN groups had a similar or 
higher antibody concentration at two weeks post ‘turnout’, suggesting that IN vaccines caused an 
immune response or delayed antibody concentration waning.  Chapter 3 observed similar 
morbidity and mortality rates between the IN and IJ vaccine primers, though mortality for the IN 
group was numerically higher.  However, the overall conclusion of the field study is that IN 
vaccines show no difference in priming ability compared to IJ vaccines. 
Chapter 2 highlights the potential benefits of heterologous vaccination methods.  This chapter 
found that calves receiving a priming MLV vaccine and boosted with a KV vaccine had a higher 
BRSV antibody concentrations then the homologous MLV groups.  Bovine herpes virus type 1 
was similar between groups at all time points except at weaning, when antibody concentrations 
were low.  Commercial IN vaccines do not have antigens for BVDV types 1 or 2, therefore these 
viruses antibody concentrations were tested homologously.  The results show that MatAb 
interference likely occurred with BVDV1, and that the MLV vaccine had a greater antibody 
response than the KV for BVDV2.  These studies provide a solid foundation for the study of 
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